Stephen Moore, M.D.
Charles E. Allen, M.D.
Scott A. Clark, M.D.
Sheraj Jacob, M.D.
Jessica E. Collins, PA-C
Nickola F. Booker, PA-C

Gastroenterology Associates of Gainesville, P.C.

Diplomates of
American Board of
Internal Medicine and
Gastroenterology

1-0
(2)

August 9, 2006

Mark McClellan, M. D.
Centers for Medicare and Medicaid Services
Department of Health & Human Services
Attention: CMS-1506-P
PO Box 8014
Baltimore, Maryland 21244-8014

Re: Medicare Program: Ambulatory Surgery Centers PPS Proposed Rule

Dear Dr. McClellan:

I am a private physician who presently treats Medicare beneficiaries in my practice. I am writing to express my grave concern with CMS' recent proposal to change the way the agency pays ambulatory surgery centers for their services, via facility fee payments.

To be brief, if the new proposal is enacted as proposed, I plan to stop performing any endoscopic procedures on Medicare patients in our ASC. All Medicare patients would have their procedures done at the hospital at an increased cost to the patient and to Medicare. I also plan to reconsider my participation in the Medicare program. Continued cuts in reimbursement over the past few years have finally reached an intolerable level.

Respectfully yours,

Stephen Moore, M. D.

SM/jk

663 Lanier Park Drive • Gainesville, Georgia 30501-2059 • Telephone 770-536-8109 • Fax 770-536-3203

2-0
(1191)
ASC's

GI of Norman, LLC

*Philip C. Bird, M.D. * Steve K. Arora, M.D. * Chintan A. Parikh, M.D. * Andrew W. Black, M.D.*
1125 N. Porter, Ste. 301
Norman, OK 73071
(405) 360-2777
Fax (405) 360-2780

Dana (2)
Joan
Carol
Alberta

Mark McClellan, M.D.
Centers for Medicare and Medicaid Services
Department of Health & Human Services
Attention: CMS-1506-P
P.O. Box 8014
Baltimore, Maryland 21244-8014

Re: Medicare Program: Ambulatory Surgery Centers PPS Proposed Rule

Dear Dr. McClellan:

I am a private practice physician who presently treats Medicare beneficiaries in my practice. I am writing to express my grave concern with CMS's recent proposal to change the way the agency pays ambulatory surgery centers for their services, via facility fee payments.

In my practice, we see a large number of Medicare patients. Treatment for a substantial percentage of these patients includes performing screening colonoscopies for those who are at average risk for colorectal cancer, as well as colonoscopies for high risk individuals and surveillance colonoscopies for those who have already been detected as having either polyps, or who have had cancerous lesions excised previously. Additionally we see a very significant number of patients with other conditions—GI bleeding, inflammatory bowel disease, gastroesophageal reflux disease (GERD), and/or Barrett's esophagus for whom ready access to an appropriate, safe, cost-efficient site for GI endoscopy is critical to either restoring them to good health, or sustaining them in good health.

Both the GAO and CMS itself have stated that the Medicare colorectal cancer screening benefit is underutilized. MEDPAC has repeatedly endorsed the concept that medical procedures and services should be site neutral. So, on its face, a proposal such as this one, which institutionalizes the concept of paying significantly more to the hospital than to the ASC, and which will likely reduce the capacity to provide GI screening colonoscopies and other GI endoscopic procedures by forcing a significant number of ASCs to close their doors to Medicare beneficiaries, if not to all patients, because Medicare's payment level will drop so precipitously that these ASCs can no longer meet their expenses and render a reasonable return on investment, seems foolish and counterproductive.

Medicare seems to be ignoring both the stated priorities of the current Administration as well as the lessons of cost management in the private sector. President Bush and his staff

are on record, on multiple occasions, stating that ASCs are a more cost-effective environment than the hospital to receive key medical services. When private sector insurers have sought to reduce total health care costs, they have actively sought to encourage patients to receive their services in the ambulatory surgery center, instead of in the hospital outpatient department. In a recent example, Blue Cross of California has announced that it will pay a 5% premium to physicians for every GI endoscopy that is performed in the ASC, rather than in the HOPD. This CMS proposal, which would always pay more to HOPDs and always pay less to ASCs, is directly antithetical to the direction adopted by the private sector insurers.

The agency's concept of budget neutrality in this proposal is incorrect, unfair and shortsighted, for multiple reasons. First and foremost, the agency proposes to increase markedly the number of procedures, from a variety of different specialties, that are performed in the ambulatory surgery center. By raising, markedly, the reimbursement for vascular, orthopedic and urologic services, much larger numbers of these services will be performed in ASCs. But in computing budget neutrality, CMS appears to believe that exactly the same pool of dollars should cover in full the payment, even if, because of expansion of the ASC approved list, millions of procedures that once were performed in the HOPD are now reimbursed under the ASC payment policy. Congress could never have intended that CMS would secure twice as many services for the same number of dollars. Every new service that is added to the ASC list, under this interpretation, forces the facility fee payment for a GI endoscopy performed in an ASC that much lower. This approach is unfair, nonsensical and bad health policy.

The reality is that for every single case that moves from the HOPD to the ASC under this expansion of the ASC approved list, the Medicare program will save money. This is so because at the current rates, ASC payments are always lower than, or at least never greater than the facility fee that CMS pays to HOPDs. Again, if the pool of dollars for ASC payments were fixed despite a large increase in the number of cases done in the ASC (because of expansions to the ASC list), then the pool of dollars paid out to HOPDs will decline, because fewer cases are likely to be done there. So, the only accurate approach to budget neutrality is to consider the impact on the total pool of BOTH ASC facility fee payments and HOPD facility fee payments. In summary, the agency currently has budget neutrality completely wrong—(1) you cannot expect the same pool of funds to cover all costs when the expansion of the ASC approved list will likely result in millions of additional cases moving to the ASC; and (2) CMS must take into account, and not ignore, the savings that are generated in HOPD payments because many cases will likely move from HOPD to the ASC setting.

In the gastroenterology area, CMS's proposed policy virtually assures results inimical to the public health. Today, when a GI procedure, such as a screening colonoscopy is performed in an ASC, that ASC receives a facility fee which on the average amounts to 89% of the facility fee CMS pays to the HOPD if that same procedure is performed there. We need to provide a bit of background relating to the effectiveness of the Medicare colorectal cancer screening benefit. Congress did the right thing in 1997 when it enacted the Medicare colorectal cancer screening benefit, and again in 2000 when it added the

average risk colonoscopy benefit. Sadly, and whether intentionally or inadvertently, CMS has done everything possible to emasculate the effectiveness and utilization of that benefit. Since 1997, CMS has cut the physician fee schedule payment for screening/diagnostic colonoscopies by almost 40%--from a little over $300, to the current level of just around $200, and trending downward (these are raw dollars—if inflation were factored in the reduction would almost certainly be in excess of 50%). According to information from the American College of Gastroenterology, no other Medicare service has been cut this much. Now, CMS issues a new proposal which would further undercut and devastate the prospects for Medicare beneficiaries to receive a colorectal cancer screening colonoscopy. In terms of the specialty that would be hurt the most by the current proposal, once again, CMS foolishly has placed gastroenterology and colonoscopies for colorectal cancer screening in its cross hairs, as by far the biggest potential loser, with the prospect of cuts from 89% of the HOPD payment to 62%.

If CMS is bound to peg ASC payments at a percentage of HOPD, it must adopt a bi-level approach, with ASCs in groups like GI and pain management at a higher tier of payment that is at or higher than the current 89% we now receive, and then a second, lower tier as the facility fee percentage for ASCs in other specialties, which are not involved in life-saving preventive services like colorectal cancer screening tests.

It is clear what will happen if this CMS proposal is adopted in anything close to its current form:

For Patients:

Utilization of the Medicare colorectal cancer screening benefit, already anemic, will be further devastated—the collision of false payment "savings" vs. sound preventive public health policy will be dramatic. Utilization of CRC screening will decline still further, cancers will go undetected, and in life and death terms, many Medicare beneficiaries will die unnecessarily because the access to sites where colonoscopies can be performed will be reduced as GI ASCs close, waiting times for screening will increase, and the overall rate of CRC screening will plummet farther.

For the Medicare System:

Medicare facility fee payments for GI services will increase, rather than decrease. Having dealt a death-blow to many GI ASCs by draconian reductions in payment, the access of Medicare beneficiaries to GI ASCs will be markedly reduced. CRC screening colonoscopies will be reduced, but the volume of diagnostic colonoscopies and endoscopies will not decline.

With fewer ASCs, a larger proportion of all GI procedures will need to be performed in the HOPD, where the facility fees CMS pays will be higher.

So, the inevitable result of this proposed CMS action, if implemented will be: (a) total Medicare costs for GI facility fees will rise (although the per unit facility fee for

decreased number of these performed in the ASC may well decline); (b) available access by Medicare beneficiaries for GI colonoscopies and other endoscopic procedures will decline; and (c) more Medicare beneficiaries will die unnecessarily from colorectal cancer will increase as screening rates decline.

It is hard to believe that these are the results the CMS is seeking, but the only way to avoid this outcome is to modify this proposal so as to increase, not decrease, the facility fees to GI ASCs. This will avoid the closure of GI ASCs, and thus avoid a reduction in access and CRC screening rates. It will also prevent an increase in the number of GI procedures performed in the more costly HOPD setting.

Respectfully submitted,



Philip C. Bird, M.D.

PCB/cmj